Sana Biotechnology, Inc. Payments to Acquire Marketable Securities
Sana Biotechnology, Inc. (SANA) reported Payments to Acquire Marketable Securities of $107.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Sana Biotechnology, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $101.67M.
- Sana Biotechnology, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $5.59M, a 232.22% increase year-over-year.
- Sana Biotechnology, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $36.08M, a 175.96% increase year-over-year.
- Sana Biotechnology, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $49.53M, a 37.69% increase year-over-year.
- Sana Biotechnology, Inc. payments to acquire marketable securities for fiscal 2025 was $87.29M, a 61.39% decline from fiscal 2024.
- Sana Biotechnology, Inc. payments to acquire marketable securities for fiscal 2024 was $226.06M, a 43.31% increase from fiscal 2023.
- Sana Biotechnology, Inc. payments to acquire marketable securities for fiscal 2023 was $157.74M, a 100.47% increase from fiscal 2022.
- Sana Biotechnology, Inc. payments to acquire marketable securities for fiscal 2022 was $78.69M, a 83.99% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $101.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $107.26M 10-Q · filed 2026-08-10 | $143.34M derived: sum of 3 quarters · filed 2026-08-10 | $192.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $5.59M 10-Q · filed 2026-05-11 | $41.67M derived: sum of 2 quarters · filed 2026-05-11 | $91.20M derived: sum of 3 quarters · filed 2026-05-11 | $91.20M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $36.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $85.61M derived: sum of 2 quarters · filed 2026-03-03 | $85.61M derived: sum of 3 quarters · filed 2026-08-10 | $87.29M 10-K · filed 2026-03-03 |
| 2025-09-30 | $49.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.53M derived: sum of 2 quarters · filed 2026-08-10 | $51.21M 10-Q · filed 2025-11-06 | $64.28M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.68M 10-Q · filed 2026-08-10 | $14.76M derived: sum of 3 quarters · filed 2026-08-10 | $50.73M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-11 | $14.76M derived: sum of 2 quarters · filed 2026-05-11 | $50.73M derived: sum of 3 quarters · filed 2026-05-11 | $113.35M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $13.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $49.05M derived: sum of 2 quarters · filed 2026-03-03 | $111.67M derived: sum of 3 quarters · filed 2026-03-03 | $226.06M 10-K · filed 2026-03-03 |
| 2024-09-30 | $35.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $98.59M derived: sum of 2 quarters · filed 2025-11-06 | $212.99M 10-Q · filed 2025-11-06 | $239.12M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $62.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $177.02M 10-Q · filed 2025-08-11 | $203.15M derived: sum of 3 quarters · filed 2026-03-03 | $263.50M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $114.39M 10-Q · filed 2025-05-08 | $140.52M derived: sum of 2 quarters · filed 2026-03-03 | $200.87M derived: sum of 3 quarters · filed 2026-03-03 | $251.71M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $86.48M derived: sum of 2 quarters · filed 2026-03-03 | $137.31M derived: sum of 3 quarters · filed 2026-03-03 | $157.74M 10-K · filed 2026-03-03 |
| 2023-09-30 | $60.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $111.19M derived: sum of 2 quarters · filed 2024-11-08 | $131.62M 10-Q · filed 2024-11-08 | $146.72M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $50.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $71.27M 10-Q · filed 2024-08-08 | $86.37M derived: sum of 3 quarters · filed 2025-03-17 | $103.99M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $20.43M 10-Q · filed 2024-05-08 | $35.54M derived: sum of 2 quarters · filed 2025-03-17 | $53.16M derived: sum of 3 quarters · filed 2025-03-17 | $73.44M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $15.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $32.73M derived: sum of 2 quarters · filed 2025-03-17 | $53.01M derived: sum of 3 quarters · filed 2025-03-17 | $78.69M 10-K · filed 2025-03-17 |
| 2022-09-30 | $17.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $37.91M derived: sum of 2 quarters · filed 2023-11-08 | $63.58M 10-Q · filed 2023-11-08 | $140.53M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $20.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $45.96M 10-Q · filed 2023-08-03 | $122.91M derived: sum of 3 quarters · filed 2024-02-29 | $371.80M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $25.68M 10-Q · filed 2023-05-08 | $102.63M derived: sum of 2 quarters · filed 2024-02-29 | $351.51M derived: sum of 3 quarters · filed 2024-02-29 | $472.25M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $76.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $325.84M derived: sum of 2 quarters · filed 2024-02-29 | $446.58M derived: sum of 3 quarters · filed 2024-02-29 | $491.39M 10-K · filed 2024-02-29 |
| 2021-09-30 | $248.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $369.63M derived: sum of 2 quarters · filed 2022-11-02 | $414.44M 10-Q · filed 2022-11-02 | $494.47M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-06-30 | $120.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $165.55M 10-Q · filed 2022-08-04 | $245.59M derived: sum of 3 quarters · filed 2023-03-16 | $509.86M derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-03-31 | $44.81M 10-Q · filed 2022-05-10 | $124.84M derived: sum of 2 quarters · filed 2023-03-16 | $389.12M derived: sum of 3 quarters · filed 2023-03-16 | |
| 2020-12-31 | $80.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $344.31M derived: sum of 2 quarters · filed 2023-03-16 | $387.43M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $264.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $307.40M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $43.12M 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $141.52M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |